Last updated: 11/06/2018 23:45:42
A 52 WEEK OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY OF ROPINIROLE IN SUBJECTS SUFFERING FROM RESTLESS LEGS SYNDROME.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A 52 WEEK OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY OF ROPINIROLE IN SUBJECTS SUFFERING FROM RESTLESS LEGS SYNDROME.
Trial description: A 52 WEEK OPEN-LABEL EXTENSION STUDY OF THE LONG-TERM SAFETY OF ROPINIROLE IN SUBJECTS SUFFERING FROM RESTLESS LEGS SYNDROME.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Dreykluft T, Karrasch J, Smuts J, Volc D, Grunstein R, Montplaisir J. The long-term safety and tolerability of ropinirole in RLS. International Congress of Parkinson’s Disease and Movement Disorders, Rome, Italy, Jun 13–17 2004. Mov Disord 2004; 19(suppl 9): S430: P1262
Medical condition
Restless Legs Syndrome
Product
ropinirole
Collaborators
Not applicable
Study date(s)
October 2002 to March 2004
Type
Not applicable
Phase
2/3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2004-04-03
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website